NCT04335383 Isolation of Human Recombinant Therapeutic Monoclonal Anti-Pseudomonas Antibodies
| NCT ID | NCT04335383 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Grenoble |
| Condition | Pseudomonas Aeruginosa |
| Study Type | OBSERVATIONAL |
| Enrollment | 30 participants |
| Start Date | 2020-10-05 |
| Primary Completion | 2026-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 30 participants in total. It began in 2020-10-05 with a primary completion date of 2026-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Pseudomonas aeruginosa is a pathogenic bacteria for human, especially in hospital settings. It can sometimes be multi-resistant to many or even to all antibiotics usually used for its treatment. The aim of the study is to isolate and produce therapeutic antibodies against the bacteria Pseudomonas aeruginosa in order to provide an alternative treatment to antibiotics in case of infection with an antibiotic-resistant strain of Pseudomonas aeruginosa.
Eligibility Criteria
Inclusion Criteria: * Patient selected in the retrospective part of the study (patient with serum containing functional anti-Pseudomonas aeruginosa antibodies) * Patient with weight ≥ 32kg. * With a follow-up visit at Grenoble University Hospital with a blood sampling for its care * Having given its written no objection to participate in the prospective phase of this project Exclusion Criteria: * Legally protected patient (minor, pregnant or nursing woman, ward or ward curated, hospitalized under duress or deprived of liberty)
Contact & Investigator
Yvan CASPAR, Dr
PRINCIPAL INVESTIGATOR
University Hospital, Grenoble
Frequently Asked Questions
Who can join the NCT04335383 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Pseudomonas Aeruginosa. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04335383 currently recruiting?
Yes, NCT04335383 is actively recruiting participants. Contact the research team at ycaspar@chu-grenoble.fr for enrollment information.
Where is the NCT04335383 trial being conducted?
This trial is being conducted at Grenoble, France.
Who is sponsoring the NCT04335383 clinical trial?
NCT04335383 is sponsored by University Hospital, Grenoble. The principal investigator is Yvan CASPAR, Dr at University Hospital, Grenoble. The trial plans to enroll 30 participants.